Precision Medicine

A new, smaller implant for back surgery promises easier procedures for surgeons and lasting relief for patients by tackling the risk of reherniation.

Cordis presents pivotal 12-month data for its innovative SELUTION SLR drug-eluting balloon, a device that could change how doctors treat clogged arteries.

With strong revenue growth and critical FDA decisions on the horizon, MannKind's leadership prepares to outline its vision for investors in Miami.

In a booming aesthetics market, one company is enlisting elite surgeons to architect the future of recovery, aiming to close a critical gap in patient care.

Beyond the prescription pad, a new concierge program in Tucson integrates advanced diagnostics and lifestyle coaching to redefine sustainable weight management.

After solving a key manufacturing flaw, CervoMed advances its promising dementia drug, neflamapimod, to a Phase 3 trial with an optimized dose.

With its lead drug for a rare blood cancer nearing European submission, Cellectar Biosciences advances its targeted radiotherapy platform on two fronts.

A new UK facility, backed by government funds, will be the only one of its kind, aiming to accelerate drug development and boost domestic life sciences.

Immunome announces stellar Phase 3 data for its desmoid tumor drug, varegacestat, and details a robust, well-funded ADC pipeline aimed at solid tumors.

The nation's leading aesthetic provider launches a Salmon DNA Facial, XTherma, and NAD+ injections, betting on the science of regenerative beauty.

Finance and governance powerhouse Suzanne Nora Johnson joins Wellcome Leap's board, a strategic move to supercharge its mission to solve health crises.

The D.C. transplant institute surpasses a historic milestone, pioneering new tech and giving thousands a second chance at life amid a national organ shortage.

Daxor reports a transformative year with 45% revenue growth, a new FDA-cleared portable analyzer, and a full pivot to a high-growth medtech company.

A new partnership leverages advanced AI and metabolomics to find novel drug targets for rare metabolic disorders, offering new hope for millions worldwide.

An AI firm known for fighting cancer is now partnering with Unilever, signaling a new era of biologically personalized consumer products and new ethical questions.

A novel drug delivery system could revolutionize Alzheimer's treatment, and Acumen Pharmaceuticals is leading the charge with its targeted therapy.

As oral GLP-1s enter the market, companies offer digital coaching to boost drug efficacy and justify soaring costs for employers and health plans.

The world's top beauty event returns to Paris, showcasing a major shift as ingestible ingredients and holistic wellness redefine the personal care industry.

A 2.5-year-old's sudden paralysis led to a high-risk, pioneering neuro-intervention that reversed a severe stroke, setting a new benchmark for pediatric care.

Popular weight-loss drugs are linked to fewer ER visits for chronic migraine, a new study finds, sparking hope and questions about a new treatment frontier.